Antonio Benedetti is appointed as Kuano’s new Chairperson
Antonio is an experienced CEO with a demonstrated history of working in the pharmaceuticals (former CEO Cycle Pharmaceuticals) industry.
£1m in seed funding raised by Kuano
Kuano closes its £1m seed round, led by ACF Investors. O2h Ventures and a syndicate of angel investors based in Cambridge, London and the U.S. Read more
Kuano graduates from Creative Destruction Lab Accelerator
Kuano is an official graduate of the Quantum stream of Creative Destruction Lab (CDL), one of the world’s top deep tech accelerators
Kuano to collaborate with the Alzheimer’s Research UK DDI
Our collaboration has the potential to expand the portfolio of chemotypes being explored targeting NOTUM in the treatment of dementia.
Kuano appoints Dr. Andy Mulvaney as Non-Executive Director
Andy is a seasoned industry executive and, in addition to hands-on experience of contributing to the formation and development of a highly successful biotech, Summit Therapeutics, Inc.(NASDAQ:SMMT), brings broad corporate, business and operational development experience to Kuano.